PURPOSE: The purpose of this study was to determine whether cholesterol, the host cell receptor for pneumolysin of Streptococcus pneumoniae, could effectively treat pneumococcal keratitis. METHODS: New Zealand White rabbits were intrastromally injected with 10(5) colony-forming units (CFUs) of S. pneumoniae D39. Corneas were treated with topical drops of 1% cholesterol every 2 hours beginning 25 hours after infection and were examined by slit lamp microscopy 24, 36, and 48 hours after infection. Rabbits were killed, and CFUs were recovered from the corneas after the final slit lamp examination (SLE). Minimal inhibitory concentration (MIC) assays of cholesterol against bacteria were performed. Specific inhibition of pneumolysin by cholesterol in the rabbit cornea was tested by intrastromal injection of pneumolysin with or without cholesterol and was compared with cholesterol inhibition of pneumolysin in vitro using hemolysis assays with rabbit erythrocytes. RESULTS: Corneas treated with cholesterol had significantly lower SLE scores 48 hours after infection than corneas treated with vehicle (P = 0.0015). Treated corneas also had significantly less log(10) CFUs than vehicle-treated corneas (P = 0.0006). Cholesterol at a 1% concentration was bactericidal to bacteria in vitro, and lower concentrations of cholesterol were partially inhibitory in a concentration-dependent manner. Cholesterol also specifically inhibited 1 mug pneumolysin in vivo and up to 50 ng pneumolysin in vitro. CONCLUSIONS: Topical cholesterol is an effective treatment for S. pneumoniae keratitis. Cholesterol not only inhibits pneumolysin, it is also bactericidal.
PURPOSE: The purpose of this study was to determine whether cholesterol, the host cell receptor for pneumolysin of Streptococcus pneumoniae, could effectively treat pneumococcal keratitis. METHODS: New Zealand White rabbits were intrastromally injected with 10(5) colony-forming units (CFUs) of S. pneumoniae D39. Corneas were treated with topical drops of 1% cholesterol every 2 hours beginning 25 hours after infection and were examined by slit lamp microscopy 24, 36, and 48 hours after infection. Rabbits were killed, and CFUs were recovered from the corneas after the final slit lamp examination (SLE). Minimal inhibitory concentration (MIC) assays of cholesterol against bacteria were performed. Specific inhibition of pneumolysin by cholesterol in the rabbit cornea was tested by intrastromal injection of pneumolysin with or without cholesterol and was compared with cholesterol inhibition of pneumolysin in vitro using hemolysis assays with rabbit erythrocytes. RESULTS: Corneas treated with cholesterol had significantly lower SLE scores 48 hours after infection than corneas treated with vehicle (P = 0.0015). Treated corneas also had significantly less log(10) CFUs than vehicle-treated corneas (P = 0.0006). Cholesterol at a 1% concentration was bactericidal to bacteria in vitro, and lower concentrations of cholesterol were partially inhibitory in a concentration-dependent manner. Cholesterol also specifically inhibited 1 mug pneumolysin in vivo and up to 50 ng pneumolysin in vitro. CONCLUSIONS: Topical cholesterol is an effective treatment for S. pneumoniae keratitis. Cholesterol not only inhibits pneumolysin, it is also bactericidal.
Authors: Anita W Rijneveld; Germie P van den Dobbelsteen; Sandrine Florquin; Theodore J Standiford; Peter Speelman; Loek van Alphen; Tom van der Poll Journal: J Infect Dis Date: 2001-11-30 Impact factor: 5.226
Authors: Pragya Parmar; Amjad Salman; C Munusamy Kalavathy; C A Nelson Jesudasan; Philip A Thomas Journal: Clin Exp Ophthalmol Date: 2003-02 Impact factor: 4.207
Authors: P David Rogers; Justin Thornton; Katherine S Barker; D Olga McDaniel; Gordon S Sacks; Edwin Swiatlo; Larry S McDaniel Journal: Infect Immun Date: 2003-04 Impact factor: 3.441
Authors: Inés Martínez; Diahann J Perdicaro; Andrew W Brown; Susan Hammons; Trevor J Carden; Timothy P Carr; Kent M Eskridge; Jens Walter Journal: Appl Environ Microbiol Date: 2012-11-02 Impact factor: 4.792
Authors: Erin W Norcross; Melissa E Sanders; Quincy C Moore; Sidney D Taylor; Nathan A Tullos; Rhonda R Caston; Sherrina N Dixon; Moon H Nahm; Robert L Burton; Hilary Thompson; Larry S McDaniel; Mary E Marquart Journal: Invest Ophthalmol Vis Sci Date: 2011-11-29 Impact factor: 4.799
Authors: Melissa E Sanders; Nathan A Tullos; Sidney D Taylor; Erin W Norcross; Lauren B King; Isaiah Tolo; Mary E Marquart Journal: Curr Eye Res Date: 2010-12 Impact factor: 2.424
Authors: Wahaj Saleem; Angela H Benton; Mary E Marquart; Shuli Wang; Waqas Saleem; Randy Vigil; Bo Huang; Anjal C Sharma Journal: Clin Plasma Med Date: 2019-12-27
Authors: Quincy C Moore; Clare C McCormick; Erin W Norcross; Chinwendu Onwubiko; Melissa E Sanders; Jonathan Fratkin; Larry S McDaniel; Richard J O'Callaghan; Mary E Marquart Journal: Ophthalmic Res Date: 2009-07-23 Impact factor: 2.892
Authors: Sherrina N Green; Melissa Sanders; Quincy C Moore; Erin W Norcross; Kathryn S Monds; Armando R Caballero; Larry S McDaniel; Sherrina A Robinson; Chinwendu Onwubiko; Richard J O'Callaghan; Mary E Marquart Journal: Invest Ophthalmol Vis Sci Date: 2008-01 Impact factor: 4.799
Authors: Robert M Q Shanks; Nicholas A Stella; Roni M Lahr; Shaoru Wang; Tara I Veverka; Regis P Kowalski; Xinyu Liu Journal: PLoS One Date: 2012-05-16 Impact factor: 3.240
Authors: Sidney D Taylor; Melissa E Sanders; Nathan A Tullos; Stephen J Stray; Erin W Norcross; Larry S McDaniel; Mary E Marquart Journal: PLoS One Date: 2013-04-05 Impact factor: 3.240